These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 33272166)

  • 21. Intestinal lymphatic transport enhances the post-prandial oral bioavailability of a novel cannabinoid receptor agonist via avoidance of first-pass metabolism.
    Trevaskis NL; Shackleford DM; Charman WN; Edwards GA; Gardin A; Appel-Dingemanse S; Kretz O; Galli B; Porter CJ
    Pharm Res; 2009 Jun; 26(6):1486-95. PubMed ID: 19280324
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Self-emulsifying Drug Delivery System Improve Oral Bioavailability: Role of Excipients and Physico-chemical Characterization.
    Zhu Y; Ye J; Zhang Q
    Pharm Nanotechnol; 2020; 8(4):290-301. PubMed ID: 32781978
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structured triglyceride vehicles for oral delivery of halofantrine: examination of intestinal lymphatic transport and bioavailability in conscious rats.
    Holm R; Porter CJ; Müllertz A; Kristensen HG; Charman WN
    Pharm Res; 2002 Sep; 19(9):1354-61. PubMed ID: 12403073
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intestinal lymphatic transport for drug delivery.
    Yáñez JA; Wang SW; Knemeyer IW; Wirth MA; Alton KB
    Adv Drug Deliv Rev; 2011 Sep; 63(10-11):923-42. PubMed ID: 21689702
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug delivery to the lymphatic system.
    Porter CJ
    Crit Rev Ther Drug Carrier Syst; 1997; 14(4):333-93. PubMed ID: 9450175
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Intestinal lymphatic transport of breviscapine orally administered in rat].
    Gong YJ; Wang JX; Zhang Y; Shen M; Fu CM; Shen T
    Yao Xue Xue Bao; 2011 Oct; 46(10):1262-7. PubMed ID: 22242462
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glucose-Based Mesoporous Carbon Nanospheres as Functional Carriers for Oral Delivery of Amphiphobic Raloxifene: Insights into the Bioavailability Enhancement and Lymphatic Transport.
    Ye Y; Zhang T; Li W; Sun H; Lu D; Wu B; Zhang X
    Pharm Res; 2016 Mar; 33(3):792-803. PubMed ID: 26553355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biological and pharmaceutical factors affecting the absorption and lymphatic delivery of ciclosporin A from gastrointestinal tract.
    Takada K; Furuya Y; Yoshikawa H; Muranishi S
    J Pharmacobiodyn; 1988 Feb; 11(2):80-7. PubMed ID: 3379567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Magnetic lymphatic targeting drug delivery system using carbon nanotubes.
    Yang F; Fu de L; Long J; Ni QX
    Med Hypotheses; 2008; 70(4):765-7. PubMed ID: 17910909
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improvement of Oral Bioavailability of N-251, a Novel Antimalarial Drug, by Increasing Lymphatic Transport with Long-Chain Fatty Acid-Based Self-Nanoemulsifying Drug Delivery System.
    Imada C; Takahashi T; Kuramoto M; Masuda K; Ogawara K; Sato A; Wataya Y; Kim HS; Higaki K
    Pharm Res; 2015 Aug; 32(8):2595-608. PubMed ID: 25715697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chylomicron-pretended nano-bio self-assembling vehicle to promote lymphatic transport and GALTs target of oral drugs.
    Mao Y; Feng S; Li S; Zhao Q; Di D; Liu Y; Wang S
    Biomaterials; 2019 Jan; 188():173-186. PubMed ID: 30359884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral bioavailability assessment and intestinal lymphatic transport of Org 45697 and Org 46035, two highly lipophilic novel immunomodulator analogues.
    Caliph SM; Faassen WA; Vogel GM; Porter CJ
    Curr Drug Deliv; 2009 Aug; 6(4):359-66. PubMed ID: 19534711
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Strategies to improve oral drug bioavailability.
    Gomez-Orellana I
    Expert Opin Drug Deliv; 2005 May; 2(3):419-33. PubMed ID: 16296764
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bioavailability enhancement strategies: basics, formulation approaches and regulatory considerations.
    Beg S; Swain S; Rizwan M; Irfanuddin M; Malini DS
    Curr Drug Deliv; 2011 Nov; 8(6):691-702. PubMed ID: 21864253
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diverse approaches for the enhancement of oral drug bioavailability.
    Fasinu P; Pillay V; Ndesendo VM; du Toit LC; Choonara YE
    Biopharm Drug Dispos; 2011 May; 32(4):185-209. PubMed ID: 21480294
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Engineering Nano- and Microparticles as Oral Delivery Vehicles to Promote Intestinal Lymphatic Drug Transport.
    Miao YB; Lin YJ; Chen KH; Luo PK; Chuang SH; Yu YT; Tai HM; Chen CT; Lin KJ; Sung HW
    Adv Mater; 2021 Dec; 33(51):e2104139. PubMed ID: 34596293
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs.
    Dahan A; Hoffman A
    J Control Release; 2008 Jul; 129(1):1-10. PubMed ID: 18499294
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intestinal absorption and intestinal lymphatic transport of sirolimus from self-microemulsifying drug delivery systems assessed using the single-pass intestinal perfusion (SPIP) technique and a chylomicron flow blocking approach: linear correlation with oral bioavailabilities in rats.
    Sun M; Zhai X; Xue K; Hu L; Yang X; Li G; Si L
    Eur J Pharm Sci; 2011 Jun; 43(3):132-40. PubMed ID: 21530655
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Different impacts of intestinal lymphatic transport on the oral bioavailability of structurally similar synthetic lipophilic cannabinoids: dexanabinol and PRS-211,220.
    Gershkovich P; Qadri B; Yacovan A; Amselem S; Hoffman A
    Eur J Pharm Sci; 2007 Aug; 31(5):298-305. PubMed ID: 17560096
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bioactive-Chylomicrons for Oral Lymphatic Targeting of Berberine Chloride: Novel Flow-Blockage Assay in Tissue-Based and Caco-2 Cell Line Models.
    Elsheikh MA; Elnaggar YSR; Otify DY; Abdallah OY
    Pharm Res; 2018 Jan; 35(1):18. PubMed ID: 29305670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.